Carol Miyake
Endocrinology, Diabetes & Metabolism · Poughkeepsie, NYNPI 1760408330
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.3% of the total across 205 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 11.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,745 and has fallen 91.0% since, to $158 in 2022.
Across 205 payments — averaging $16.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$392
- GSK$364
- AbbVie$358
- AstraZeneca$338
- Lilly USA, LLC$234
- Johnson & Johnson$231
- plus $2K from 25 others
What the payments were for
- Food & beverage$3,37497%
- Education$361%
- Gifts$592%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 30 | $392 |
| GSK | 23 | $364 |
| AbbVie | 17 | $358 |
| AstraZeneca(2 entities) | 23 | $338 |
| Lilly USA, LLC | 16 | $234 |
| Johnson & Johnson | 14 | $231 |
| Amgen | 13 | $204 |
| Corcept Therapeutics | 5 | $142 |
| Mannkind Corporation | 6 | $140 |
| Pfizer | 9 | $134 |
| Abbott | 6 | $104 |
| Mylan Specialty L.p. | 4 | $78 |
| Amneal Pharmaceuticals LLC | 4 | $77 |
| IBSA Pharma Inc. | 4 | $75 |
| Sanofi-aventis U.S. LLC | 3 | $65 |
| Recordati_rare_diseases_inc. | 1 | $64 |
| Radius Health, Inc. | 3 | $52 |
| Medtronic(2 entities) | 3 | $52 |
| Bayer | 3 | $48 |
| Boehringer Ingelheim | 3 | $45 |
| Dexcom, Inc. | 1 | $38 |
| Xeris Pharmaceuticals, Inc. | 2 | $38 |
| Merck | 2 | $31 |
| Apria Healthcare LLC | 1 | $30 |
| Endo Pharmaceuticals Inc. | 2 | $29 |
| Insulet Corporation | 2 | $25 |
| Mallinckrodt Enterprises LLC | 1 | $18 |
| Ipsen Biopharmaceuticals, Inc | 1 | $18 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
| Circassia Inc. | 1 | $15 |
| Novartis | 1 | $14 |
How this compares
$3,470 in reported general payments places this provider in the 65th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
See all endocrinology, diabetes & metabolism providers in New York →
Other endocrinology, diabetes & metabolism in Poughkeepsie
- Robert BuschAlbany$2.7M
- Michael ShanikSmithtown$1.2M
- Ajay ChaudhuriBuffalo$888K
- Vinay KapoorManhasset$820K
- John BilezikianNew York$809K
- Barbara HirschManhasset$746K
- Martin GrajowerBronx$713K
- Anastasios ManessisNew York$656K
- Jonas LeibowitzYonkers$613K
- Philip OtterbeckStaten Island$575K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.